FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, namely to a PD-1-chimeric cytokine receptor containing: ectodomain PD-1, a transmembrane domain of thrombopoietin receptor (TpoR), a Janus kinase (JAK) binding domain and a STAT attracting domain, as well as a polynucleotide coding it. Also disclosed is a vector and a cell containing said polynucleotide, as well as a method for producing said cell. Invention also relates to a kit and a pharmaceutical composition containing said cell.
EFFECT: invention is effective for treating cancer.
57 cl, 17 dwg, 11 tbl, 6 ex
Title | Year | Author | Number |
---|---|---|---|
POLYPEPTIDE COMPRISING ANTIGEN-BINDING DOMAIN AND TRANSPORTING SEGMENT | 2018 |
|
RU2841528C2 |
ANTIGENIC PEPTIDES FOR PREVENTION AND TREATMENT OF B-CELL HEMOBLASTOSIS | 2020 |
|
RU2833806C1 |
BCMA-SPECIFIC CHIMERIC ANTIGEN RECEPTORS CONTAINING IL-6 SIGNALLING BLOCKER | 2023 |
|
RU2828294C1 |
BISPECIFIC ANTIBODIES AND THEIR APPLICATIONS | 2022 |
|
RU2821577C2 |
PROPERDIN ANTIBODIES AND PRODUCTION THEREOF | 2021 |
|
RU2830308C1 |
SOLUBLE ACE2, FUSED PROTEIN THEREOF AND METHODS OF USING THEM | 2021 |
|
RU2837537C1 |
MONOCLONAL ANTIBODIES AGAINST THE RECEPTOR-BINDING DOMAIN OF SARS-COV-2 SPIKE PROTEIN AND THEIR ANTIGEN-BINDING FRAGMENTS ENCODING THEIR NUCLEIC ACIDS, AS WELL AS METHODS OF THEIR USE | 2021 |
|
RU2800649C2 |
IDE ANTIBODIES AND USE THEREOF | 2020 |
|
RU2839026C1 |
MUS MUSCULUS 5B9 HYBRID CULTIVATED ANIMAL CELLS- A PRODUCER OF MOUSE MONOCLONAL ANTIBODY 5B9, MONOCLONAL MOUSE ANTIBODY 5B9 AND RECOMBINANT CHIMERIC (MOUSE-HUMAN) ANTIBODY XI5B9, NEUTRALIZING RICIN RICINUS COMMUNIS | 2022 |
|
RU2802436C1 |
LYSE VARIANT AND METHOD FOR PRODUCING L-ARGININE USING SAME | 2022 |
|
RU2840267C2 |
Authors
Dates
2024-10-08—Published
2020-02-28—Filed